← Al het nieuws

Hollandbio welcomes Cortalix

Hollandbio connects, represents and supports the Dutch biotech sector. We are very proud to represent more than 270 companies: from start-ups, small and medium-sized enterprises to large companies, active in health, nutrition or biobased economy. Today we welcome our newest member, Cortalix, a pharma-biotech company in Groningen that develops radiopharmaceuticals and immunotherapeutics from its synthetic nanobody development platform. The company operates from the Zernike Campus in Groningen and aims to collaborate with pharmaceutical companies, CROs, and research groups to make a valuable contribution to the Life Sciences & Health community. 

Nanobodies, also known as the next generation of antibodies, have many advantages over regular antibodies. They are smaller, less complex, more stable, easier to design and produce, and ultimately cheaper and faster to develop. The first nanobodies have already been approved as marketed drugs, and more will follow soon. 

Cortalix operates on a three-pillar business model: 

  1. Internal Programs: Developing nanobody clinical candidates targeting PDGFRA, PDGFRB, FAP, IGF2R, EGFR, among others, for immunoPET/RT and immunotherapy in fibrosis and cancer. These programs are available for licensing. 
  2. Partner Programs: Seeking collaborations with companies and institutions for the development of nanobody radiopharmaceuticals and immunotherapeutics for novel targets. 
  3. Fee-for-Services: Offering stand-alone nanobody projects, on a fee-for-service basis. 

Cortalix’s platform of synthetic nanobody libraries no longer requires animals, enabling us to quickly select new nanobodies displaying high binding affinity for any target of interest. Moreover, we are expanding towards low liability and humanized libraries for clinical applications. Because Cortalix has many years of experience in the development of radiopharmaceuticals, with one product in clinical trials, we are highly skilled in genetic engineering, bioconjugation, and clinical trial requirements for your selected nanobodies. 

For more information about nanobodies or Cortalix, please visit their website